Skip to main content
US EQUITIES CLOSED CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
TERMINAL
XG

XGNStock

Nasdaq Global Market · Healthcare

$3.91 last close 2026-11-16
Open in terminalCompare
Price alert

Verdicts genuinely change. Free email alert the moment XGN's does — no target price to set, unlike a price alert.

Sharia status
COMPLIANT
Per our in-house ratio engine
4 of 7 pass our own screen — the standards disagree
Purification 0.43% *HTR non-permissible income 0.43%
🕌Open research, not a fatwa — verify with your own scholar.

Trade setup

Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.

SEPARATE FROM SHARIAH
👀 WATCH — Smart Money Accumulating
This is a divergence signal — the price is weak but smart money is loading up. Insiders just bought $64.1M of their...
Scores: 3 bullish / 3 bearish
41
of 100
Setup confidence — system conviction, not win probabilityD

Trade plan

Posted with a stop, a target and the level that invalidates it. It resolves into the public record either way.

BULL_FLAG · SCALP
Entry
$5.40
Stop
$5.33
Target
$5.54
Risk : Reward 2.0R

Why this signal?

The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.

Structure0 of 5 timeframes bullish · 87.0% aligned
VWAPPrice below VWAP ($4.61)
VolumeRelative volume 13.8× the 20-day average
Momentum10-day rate of change -50.4%
Overall readWATCH — Smart Money Accumulating

XGN is currently considered halal (Sharia-compliant), per our in-house ratio engine. See the full ratio breakdown and business-activity screen below for the reasoning.

This sits among 438 compliant Healthcare stocks we track. See compliant Healthcare stocks →

Market & analysts
Wall Street consensus
BUY
12 analysts
Price target
$9.43
+141.1% · 7 analysts
Institutional own.
44.9%
of shares
Momentum (10d)
-50.4%
rate of change
SMC grade
D · 41
87.0% aligned
0.43% *
Purification ratio (secondary provider, uncertain)
0.43%
Non-permissible income — HTR, from filings (2025-12-31)
D · 41
SMC grade — 87.0% timeframe alignment
-50.4%
Rate of change (10d)
BUY
Wall Street consensus (12)
$9.43
Price target (+141.1%) · 7 analysts
44.9%
Institutional ownership

🕌 In-house Compliance Research

Computed from published company financials, balance sheet as of 2026-09-30. These ratios come from the issuer's own published statements rather than structured SEC data.

Business activity: cleared (no excluded categories detected)

AAOIFI Pass 3 of 3 ratios pass
RatioValueThresholdResult
Interest-bearing debt 12.62% 30.00% Pass
Interest-bearing investments 13.60% 30.00% Pass
Non-permissible income 0.43% 5.00% Pass
Usmani Fail 2 of 4 ratios pass
RatioValueThresholdResult
Interest-bearing debt 51.96% 33.00% Fail
Interest-bearing investments 51.11% 33.00% Fail
Non-liquid assets 28.15% at least 20.00% Pass
Non-permissible income 0.43% 5.00% Pass
MSCI Fail 1 of 4 ratios pass
RatioValueThresholdResult
Interest-bearing debt 47.44% 33.33% Fail
Cash + interest-bearing securities 51.11% 33.33% Fail
Accounts receivable 71.85% 33.33% Fail
Non-permissible income 0.43% 5.00% Pass
FTSE Fail 1 of 4 ratios pass
RatioValueThresholdResult
Interest-bearing debt 41.21% 33.33% Fail
Cash + interest-bearing securities 51.11% 33.33% Fail
Accounts receivable 71.85% 50.00% Fail
Non-permissible income 0.43% 5.00% Pass
Dow Jones Islamic Market Pass 4 of 4 ratios pass

Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 9.66% 33.00% Pass
Cash + interest-bearing securities 10.40% 33.00% Pass
Accounts receivable 4.22% 33.00% Pass
Non-permissible income 0.43% 5.00% Pass
S&P Shariah Pass 4 of 4 ratios pass

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 12.58% 33.00% Pass
Cash + interest-bearing securities 13.55% 49.00% Pass
Accounts receivable 5.50% 49.00% Pass
Non-permissible income 0.43% 5.00% Pass
MSCI M-Series Pass 4 of 4 ratios pass

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 12.58% 33.33% Pass
Cash + interest-bearing securities 13.55% 33.33% Pass
Accounts receivable 19.05% 49.00% Pass
Non-permissible income 0.43% 5.00% Pass

Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.

How close is it to flipping?

Every current reading against its own line, closest first. A verdict is only as durable as that distance.

AAOIFI Standard 21 (% of market cap)non permissible income ratio 4.6pts
Usmani (% of total assets)non permissible income ratio 4.6pts
Dow Jones Islamic Market (% of 24-mo avg market cap)non permissible income ratio 4.6pts
MSCI Islamic Index (% of total assets)receivables ratio 38.5pts
FTSE Shariah Global Equity Index Series (% of total assets)receivables ratio 21.9pts
Usmani (% of total assets)debt ratio 19.0pts

The numbers the ratios are built from

Read from XGN's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.

LineFigureAs reportedRead from
RevenueTotal revenue for the period $66.6M 2025-12-31 RevenueFromContractWithCustomerExcludingAssessedTax
Interest-bearing debtShort and long-term borrowings $22.8M 2026-09-30 LongTermDebtNoncurrent, LongTermDebtCurrent
Cash and interest-bearing securitiesCash, equivalents and marketable securities $28.3M 2026-09-30 CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
Total assetsBalance sheet total $55.4M 2026-09-30 Assets
Market capDenominator for AAOIFI $208.1M live quote price x shares
36-month average market capDenominator for S&P Shariah and MSCI M-Series $98.6M 756 trading days closes x shares
24-month average market capDenominator for Dow Jones Islamic Market $129.9M 504 trading days closes x shares
Non-permissible revenueInterest and excluded income $289.0K 2025-12-31 InvestmentIncomeInterest

Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.

What changed, and when

Verdict history for XGN. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.

  • 2026-09-07 No change recorded No verdict change for XGN has been recorded since tracking began. The scan ledger records that the compliance detectors ran, not which symbols each pass covered.

Tracked since 2026-09-07.

Tracked investors holding XGN
InvestorFirmPositionWeightAs of
Peter Brown Renaissance Technologies $0M 0.0% 2026-09-30
Ken Griffin Citadel Advisors $0M 0.0% 2026-06-30

From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.

8.747.225.694.172.652025-11-172026-05-192026-11-16

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
3.32
S2
3.58
S1
3.86
PIVOT
4.12
R1
4.39
R2
4.66
R3
4.93

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

7-day expected range
7.64 – 9.80
±12.38% from 8.72, made 2026-09-28 · resolves 2026-10-05
STRONG BUY
from 19 indicators
74.9% of our last 10571 forecasts — across every instrument we forecast, not just this one — landed inside their stated range, and 50.2% called the direction correctly.

Technical Summary

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

STRONG SELL
19 indicators
OscillatorsBUY
4 buy · 0 neutral · 3 sell
Moving averagesSTRONG SELL
0 buy · 0 neutral · 12 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)27.90BUY
Stochastic %K (14)1.69BUY
CCI (20)-160.20BUY
Williams %R (14)-98.31BUY
MACD (12,26,9)-0.45SELL
ROC (10)-53.16SELL
Momentum (10)-4.46SELL
EMA (10)5.58SELL
SMA (10)6.01SELL
EMA (20)6.49SELL
SMA (20)6.97SELL
EMA (30)6.88SELL
SMA (30)7.38SELL
EMA (50)7.07SELL
SMA (50)7.63SELL
EMA (100)6.72SELL
SMA (100)6.71SELL
EMA (200)5.89SELL
SMA (200)5.12SELL

About XGN

Healthcare · Diagnostics & Research

Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company's lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus platform, a cornerstone of the SLE assessment that begins by quantifying the level of CB-CAPs biomarkers (EC4d and BC4d) in the patient's blood; and AVISE APS that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE Anti-Histone, a test for autoantibodies to histone proteins; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP, a biomarker-driven RA prognostic test. Further, the company offers AVISE SLE Monitor, a blood test that employs CB-CAPs technology; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop T-Cell biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

exagen.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

Latest Signal — 2026-11-11

BULL FLAG
Type · SCALP
5.40
Entry
5.33
Stop
5.54
Target
LOSS
Outcome · exit 5.33 (-1.30%)

Stop 5.33 Now 3.91 Target 5.54

Verdict

👀 WATCH — Smart Money Accumulating

This is a divergence signal — the price is weak but smart money is loading up. Insiders just bought $64.1M of their own stock and 91% of Wall Street analysts say Buy. RSI near oversold means sellers may be exhausted. This is how bottoms form — smart money accumulates before price turns. **Don't buy yet.** Wait for RSI to bounce above 35 and price to stop making lower lows — that confirms the turn. Set `!alert XGN [current price + 5%]` to catch the reversal.

Scores: 3 bullish / 3 bearish

Grade verdict

Weak — low conviction, small size or skip

SMC — Top Down

Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.

TimeframeBiasBars
📅 Daily BEARISH 64
⏰ 4H BEARISH 34
🕐 1H BEARISH 98
⏱ 15-Min RANGING 130
⏲ 5-Min RANGING 234

Momentum & Volume

Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.

-50.4%
Rate of change (10d)
13.8×
Volume vs its 20-day average
-0.80
MACD (no fresh cross)
$3.92
Volume POC (today)
$3.90 – $4.06
Value area

Peer Movement

How the rest of the sector moved over the same window. Context for a price move, never a cause of one.

Peer movement computing — it will appear here on its own.

Before you act on this

The questions worth asking about any verdict on this page, answered plainly.

Is this a fatwa?

No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.

Why can the standards disagree?

Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.

How often is this re-screened?

Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.

Do I need to purify dividends?

If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.

Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.

Compare with

Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.

Peer screening computing — it will appear here on its own.

Insider Activity (90d)

Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.

CLUSTER BUY   4 buys · 4 sells

Recent: Chernett Jorey sold 2610040 sh @ $6.14 (2026-11-06); Chernett Jorey sold 2587504 sh @ $4.65 (2026-11-12); Chernett Jorey sold 2529436 sh @ $4.08 (2026-11-13)

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.

NEUTRAL   report date 2026-11-03 · Asset managers net 928584 (+5135)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.